Can offer a prolactin lowering effect with a single oral dose1
Onset of action occurs within 3 hours.1
Sustained action for 7 to 28 days in hyperprolactinaemia patients and up to 14 to 21 days in puerperal patients.1
Higher affinity for dopamine receptor–binding sites than bromocriptine.2,*
DOSTINEX is a long-acting D2 dopamine agonist that directly stimulates receptors in the pituitary gland, decreasing the production of prolactin.
Watch the short film (4 minutes) below celebrating 25 years of manufacture of DOSTINEX at Ascoli in Italy.
Learn more about the dosing for DOSTINEX
View clinical trial data to show proven efficacy in hyperprolactinaemia & lactation suppression with DOSTINEX
View the safety profile for DOSTINEX
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021